STOCK TITAN

Terns Pharmaceuticals, Inc. - TERN STOCK NEWS

Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.

The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.

One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.

Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.

Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.

For more information, please visit their website at www.ternspharma.com.

Rhea-AI Summary
Terns Pharmaceuticals will be participating in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023. The event will be webcasted live and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.24%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Summary

Terns Pharmaceuticals, Inc. announced significant leadership changes and reported financial results for Q4 and the full year ending December 31, 2022. The company appointed Emil Kuriakose as chief medical officer for oncology, enhancing its R&D capabilities. As of December 31, 2022, Terns held $283 million in cash, sufficient to fund operations into 2026. For Q4, the net loss was $15.8 million, slightly up from $14.2 million year-over-year. R&D expenses rose to $10.7 million, while G&A expenses increased to $6.2 million. License revenue remained stagnant at $0, indicating a focus on clinical development over commercial activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.24%
Tags
Rhea-AI Summary

Terns Pharmaceuticals has appointed Emil Kuriakose, M.D., as Chief Medical Officer for oncology, effective May 1, 2023. Dr. Kuriakose has over a decade of experience in clinical development, notably in oncology, previously serving as Chief Medical Officer at Calithera Biosciences and holding key roles at Novartis. His expertise is expected to advance Terns' clinical program for TERN-701, targeting chronic myeloid leukemia (CML), addressing significant unmet needs in treatment options. Kerry Russell, M.D., will transition to Chief Medical Officer for Terns’ metabolic programs focusing on NASH and obesity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
management

FAQ

What is the current stock price of Terns Pharmaceuticals (TERN)?

The current stock price of Terns Pharmaceuticals (TERN) is $5.86 as of December 20, 2024.

What is the market cap of Terns Pharmaceuticals (TERN)?

The market cap of Terns Pharmaceuticals (TERN) is approximately 503.3M.

What does Terns Pharmaceuticals, Inc. specialize in?

Terns Pharmaceuticals specializes in discovering and developing molecularly-targeted, oral, small-molecule drugs for liver diseases and cancers.

Where is Terns Pharmaceuticals located?

Terns Pharmaceuticals is based in San Mateo, California and Shanghai, China.

What is TERN-501 and what disease does it target?

TERN-501 is an investigational orally administered thyroid hormone receptor-β (THR-β) agonist developed for the treatment of non-alcoholic steatohepatitis (NASH).

What are the main therapeutic areas Terns Pharmaceuticals focuses on?

Terns Pharmaceuticals focuses on oncology, obesity, and non-alcoholic steatohepatitis (NASH).

What is the significance of TERN-701?

TERN-701 is an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML) and represents a novel class of therapy with superior efficacy and safety profiles.

How is Terns Pharmaceuticals funded for its operations?

Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, which they expect to support planned operating expenses into 2026.

What recent achievement has Terns Pharmaceuticals made in clinical trials?

Terns Pharmaceuticals recently announced positive top-line data from its Phase 2a DUET clinical trial of TERN-501 for NASH, showing significant improvements in liver fat content and fibro-inflammation markers.

What is TERN-601 being developed for?

TERN-601 is a small-molecule GLP-1 receptor agonist being developed for the treatment of obesity.

What is the main objective of Terns Pharmaceuticals?

The main objective of Terns Pharmaceuticals is to bring novel, effective small-molecule therapies to market that address significant unmet medical needs globally.

Where can I find more information about Terns Pharmaceuticals' research and development activities?

You can find more information about Terns Pharmaceuticals' research and development activities on their official website at www.ternspharma.com.

Terns Pharmaceuticals, Inc.

Nasdaq:TERN

TERN Rankings

TERN Stock Data

503.26M
77.25M
0.14%
97.78%
4.68%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FOSTER CITY